Form 4: Pfizer Executive Vice President Payal Sahni Reports Stock Transactions

Payal Sahni, an Executive Vice President at Pfizer, reported the earn-out of stock appreciation rights and related transactions on February 22, 2025.

Summary

• On February 22, 2025, Payal Sahni, an Executive Vice President of Pfizer Inc., reported transactions involving Pfizer's common stock.
• The transactions included the earn-out of 12,714 stock appreciation rights at a price of $30.17.
• Shares were withheld to satisfy tax obligations (568 shares at $26.3) and to cover the exercise price of the stock appreciation rights (11,343 shares at $26.08).
• Following these transactions, Sahni directly owns 25,188 shares of Pfizer common stock and indirectly owns 12,938 shares through a Rule 16b-3 plan.

Sentiment

Score: 5

Explanation: This is a neutral report on stock transactions related to executive compensation. It doesn't inherently indicate positive or negative sentiment about the company's performance.

Industry Context

This filing is a routine disclosure related to executive compensation and stock ownership, common in publicly traded companies like Pfizer. It reflects standard practices for equity-based compensation and compliance with SEC regulations.

Comparison to Industry Standards

• Executive compensation packages including stock appreciation rights are common in the pharmaceutical industry.
• Companies like Johnson & Johnson, Merck, and AbbVie also utilize similar equity-based compensation to align executive interests with shareholder value.
• The reporting requirements under Section 16 of the Securities Exchange Act are standard practice for all publicly traded companies in the US.

Stakeholder Impact

• The transactions have a minor impact on shareholders as they relate to executive compensation and do not represent a significant change in the company's financial position.

Key Dates